Latest News

High-efficacy MAbs in MS: an update

November 25, 2015  

ECTRIMS highlights

Efficacy results
Monitoring and safety issues
Commentary by Dr. Paul S. Giacomini, Associate Director, MS Clinic, Montreal Neurological Hospital and Institute, Assistant Professor, Department of Neurology and Neurosurgery, McGill University

Natalizumab and alemtuzumab are the two high-efficacy monoclonal antibodies typically used to treat aggressive multiple sclerosis and patients with an inadequate response to prior therapies. New data on the use of these agents were presented at the 31st congress of the European Committee for Treatment and Research in MS (ECTRIMS). The following summarizes some of the research addressing efficacy, mode of action and safety considerations. Read More

Depression in PD often untreated despite improved detection

November 18, 2015  

A retrospective analysis of the U.S. National Parkinson’s Foundation (NPF) database has found that clinical recognition of depression in Parkinson’s disease has improved but almost one-half of patients remain untreated (Bega et al. J Parkinsons Dis 2014; epublished July 17, 2014; free full text at http://iospress.metapress.com/content/92617284j0410402/fulltext.pdf). The study was part of the NPF’s Quality Improvement Initiative. Read More

TOPICS:

New data on first-line oral therapies in MS

November 4, 2015  


ECTRIMS highlights

Long-term data
Safety studies
Comment: Dr. Mark S. Freedman, Director, Multiple Sclerosis Research Unit, The Ottawa Hospital, Ottawa, Canada

The 31st congress of the European Committee for Treatment and Research in MS (ECTRIMS) featured new research on current therapies for multiple sclerosis. In Canada, two oral therapies – teriflunomide and dimethyl fumarate (DMF) – are routinely used as first-line agents. The following summarizes key data for these two therapies presented at ECTRIMS. Read More